🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Exudative Age-Related Macular Degeneration

Progression Suppression and Retinal Regression in VEGF-resistant AMD NCT07005323NA3 sites📍 Nagoya📍 Amagasaki📍 Ube PharmaBio Corporation · Tests: Pars plana vitrectomy Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD) NCT05803785Phase 12 sites📍 Sydney📍 Sydney Benobio Co., Ltd. · Tests: BBC1501 Real-world Study of Aflibercept 8 mg in nAMD NCT07640997n/a27 sites📍 Beijing📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Aflibercept 8mg Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting NCT05093374Phase 41 site📍 Vienna Medical University of Vienna · Tests: anti-VEGF agent, anti-VEGF agent Ethical Issues of Using Gene Therapy in the Treatment of AMD NCT07004361n/a1 site📍 Nantes Nantes University Hospital Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration NCT07064759Phase 3126 sites📍 Scottsdale📍 Sun City📍 Tucson 4D Molecular Therapeutics · Tests: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration NCT07587515Phase 1, Phase 27 sites📍 Beverly Hills📍 Modesto📍 Wake Forest Eyconis INC. · Tests: EYC-0305 DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information. NCT07308639n/a1 site📍 Leverkusen Bayer · Tests: anti-VEGF medication Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration NCT07367282Phase 45 sites📍 Seongnam📍 Seoul📍 Seoul Junyeop Lee · Tests: Faricimab Injection [Vabysmo] Gene Therapy(FT-003) for Wet AMD NCT06492863Phase 1, Phase 21 site📍 Tianjin Frontera Therapeutics · Tests: FT-003 A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO NCT07205887Phase 255 sites📍 Scottsdale📍 Scottsdale📍 Glendale EyeBiotech Ltd. · Tests: Remigromig, Aflibercept 2.0 mg Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD. NCT06271330n/a1 site📍 Nantes Nantes University Hospital · Tests: Faricimab Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context NCT03577041n/a1 site📍 Amiens Centre Hospitalier Universitaire, Amiens Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration NCT07630649Phase 212 sites📍 Phoenix📍 Bakersfield📍 Fullerton Adverum Biotechnologies, Inc. · Tests: Ixo-vec Extension Study for the Port Delivery System With Ranibizumab (Portal) NCT03683251Phase 3165 sites📍 Phoenix📍 Phoenix📍 Phoenix Hoffmann-La Roche · Tests: PDS Implant with Ranibizumab 100 mg/mL Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients NCT06929507NA2 sites📍 Alexandroupoli📍 Alexandroupoli University Hospital, Alexandroupolis · Tests: Intravitreal injection of Faricimab or Aflibercept 2 mg Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD NCT06672536Phase 1, Phase 21 site📍 Tianjing Sinocelltech Ltd. · Tests: SCT520FF, SCT520FF, SCT520FF, EYLEA 2 MG MMP-9 Inhibition for Recalcitrant Wet AMD NCT04504123Phase 21 site📍 Iowa City University of Iowa · Tests: Doxycycline Hyclate, Placebo Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration NCT07776522Phase 216 sites📍 Beijing📍 Beijing📍 Jilin City West China Hospital · Tests: JWK001, Aflibercept (2.0 mg) A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) NCT04853251Phase 452 sites📍 Mesa📍 Bakersfield📍 Huntington Beach Genentech, Inc. · Tests: PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection) Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) NCT07007065Phase 3138 sites📍 Mesa📍 Sun City📍 Campbell AbbVie · Tests: Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration NCT05197270Phase 1, Phase 226 sites📍 Phoenix📍 Oxnard📍 Sacramento 4D Molecular Therapeutics · Tests: 4D-150 IVT, Aflibercept IVT A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD NCT07275840Phase 21 site📍 Shanghai Innovent Biologics Technology Limited (Shanghai R&D Center) · Tests: IBI302 8mg dose Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER). NCT04663750Phase 342 sites📍 Bonn📍 Hamburg📍 Ludwigshafen King's College Hospital NHS Trust · Tests: Pars plana vitrectomy, Intravitreal 2 mg aflibercept will be injected at baseline then monthly for two further doses, t… CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I) NCT06031727EARLY Phase 12 sites📍 Shanghai📍 Tianjin HuidaGene Therapeutics Co., Ltd. · Tests: HG202 Regulatory Post-Marketing Surveillance Study for Brolucizumab NCT04985487n/a28 sites📍 Daegu📍 Goyang-si📍 Guri-si Novartis Pharmaceuticals · Tests: brolucizumab Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR) NCT07317934Phase 336 sites📍 Hefei📍 Beijing📍 Beijing Innostellar Biotherapeutics Co.,Ltd · Tests: LX102, Aflibercept Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting NCT07249216NA1 site📍 Singapore Singapore National Eye Centre · Tests: Faricimab, Ranibizumab Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection NCT07446582n/a1 site📍 Woodbridge AI-Spectral · Tests: Retina imaging device (MSI-120) and AI (DeepMSI AI) Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients NCT07053358EARLY Phase 11 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: LX111 Injection
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy